Household Study of COVID-19, Influenza and RSV Burden, Transmission Dynamics and Viral Interaction in South Africa (PHIRST-C)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05277298 |
Recruitment Status : Unknown
Verified March 2022 by National Institute for Communicable Diseases, South Africa.
Recruitment status was: Active, not recruiting
First Posted : March 14, 2022
Last Update Posted : March 14, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
SARS-CoV-2 Infection Influenza Respiratory Syncytial Virus (RSV) |
Study Type : | Observational |
Actual Enrollment : | 1200 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Prospective Household Study of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus Community Burden, Transmission Dynamics and Viral Interaction in South Africa (the PHIRST-C Study) |
Actual Study Start Date : | July 1, 2020 |
Estimated Primary Completion Date : | December 30, 2022 |
Estimated Study Completion Date : | December 31, 2022 |
- Describe the symptomatic fraction of SARS-CoV-2 infections among individuals in household cohort in an rural and urban setting, South Africa 2020/2021. [ Time Frame: 14 months ]The proportion of SARS-CoV2 infection that are symptomatic. This will be stratified by age, underlying conditions, HIV infection.
- Describe the household secondary infection risk of SARS-CoV-2 infection among individuals in a household cohort in an rural and urban setting, South Africa 2020/2021. [ Time Frame: 14 months ]The number of secondary cases in a household divided by the total number of susceptible gives the secondary attack risk during the 14months of follow-up. This will be explored by underlying conditions, age and HIV status
- Describe the serial interval for SARS-CoV-2 in households over 14 months of follow-up in an urban and rural setting, South Africa 2020/2021 [ Time Frame: 14 months ]Calculate the time between successive cases in a each household as documented by onset of symptoms and/or PCR positive test.
- Describe the duration of shedding of SARS-CoV-2 in a household cohort in an rural and urban setting, South Africa 2020/2021. [ Time Frame: 14 month ]The duration of PCR positive SARS-CoV-2 infection in individual over 14 months of follow-up, including describing the interval by age, HIV status and underlying conditions.
- Describe the incidence of infection by PCR and serology in a household cohort in a rural and urban setting, South Africa 2020/21 [ Time Frame: 14 months ]The number of new cases of symptomatic illness recorded by symptoms reported cohort over the 14 months of follow-up. Including estimating a person time to follow-up incident rate
- Describe the incidence illness by PCR and/or serology in a household cohort in a rural and urban setting, South Africa 2020/21 [ Time Frame: 14 months ]Describe the incidence of infection by PCR and serology in a household cohort over 14 months of follow-up, in a rural and urban setting, South Africa 2020/21
Biospecimen Retention: Samples Without DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 0 Days to 99 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Mpumalanga Province site
The population is approximately 120,000 people living in 20,000 households While HIV prevalence is high, life expectancy is improving with marked epidemiological transition leading to rising prevalence of non-communicable disease including cardio-metabolic conditions and stroke.
North West Province Site
Klerksdorp is located in the local municipality of Matlosana in North West Province and has a population of over 385,000 people and is 115 km2. The townships are organized into extensions that include mostly single-family houses and shacks. Prevalence of HIV in Klerksdorp is approximately 12%.
Inclusion Criteria:
- Households/individuals that consent to participate to the study; and that are planning to reside in the selected community for the duration of the study.
- Provide at least one serum sample in the intensive follow up period, for individuals five years and older and
- Households should have at least 3 or more.
Exclusion Criteria:
Households that:
- Non-eligible households will be households that were not randomly selected, that were selected but did not consent to participate to the study or, that have >20% of household members who do not consent for inclusion in the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05277298
South Africa | |
MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), Bushbuckridge, South Africa | |
Agincourt, Mpumalanga, South Africa, 1256 | |
Perinatal HIV Research | |
Klerksdorp, North West Province, South Africa, 4538 |
Principal Investigator: | Kathleen Kahn, MD, PhD | MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), Bushbuckridge, South Africa | |
Principal Investigator: | Neil Martinson, MD, PhD | Perinatal HIV Research Unit, Johannesburg |
Responsible Party: | National Institute for Communicable Diseases, South Africa |
ClinicalTrials.gov Identifier: | NCT05277298 |
Other Study ID Numbers: |
PHIRST-C |
First Posted: | March 14, 2022 Key Record Dates |
Last Update Posted: | March 14, 2022 |
Last Verified: | March 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | The study investigators will update the study results to the clinicaltrials.gov site and publish interim results in peer review journals within 6 months of study start. |
Supporting Materials: |
Study Protocol Informed Consent Form (ICF) |
Time Frame: | Protocol informed consent will be uploaded to PHIRST-C webpage by by 31/1/2021. |
Access Criteria: | open access, will be added once available |
URL: | https://www.nicd.ac.za/centres/centre-for-respiratory-disease-and-meningitis/ |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
SARS-CoV-2 influenza RSV household transmission COVID-19 |
Influenza, Human COVID-19 Respiratory Tract Infections Infections Orthomyxoviridae Infections RNA Virus Infections Virus Diseases |
Respiratory Tract Diseases Pneumonia, Viral Pneumonia Coronavirus Infections Coronaviridae Infections Nidovirales Infections Lung Diseases |